L’infection par le virus du Chikungunya est devenu en quelques années un problème de santé publique. D’abord limitée dans les régions tropicales et subtropicales, la diffusion mondiale du vecteur de l’infection couplée à la migration humaine et aux adaptations du virus contribue à la survenue de phénomènes épidémiques fréquents et touchant de nombreux territoires jusqu’aux pays tempérés. Dans les prochaines décades, la population des 65 ans ou plus sera probablement largement impactée lors des épidémies. Les conséquences de la maladie dans cette population est méconnu du fait de l’absence de données d’observation disponibles. Or, les spécificités de cette population sont connues (risque de comorbidité associée, immunosenescence, modifications physiologiques affectant le système rénal, cardiaque, pulmonaire…) et influencent fortement son mode de réponse et sa capacité à supporter un épisode infectieux. A travers l’observation et le suivi de la cohorte ChikOld constituée de 687 sujets âgés de 65 ans ou plus ayant contracté ou non la maladie en 2014, nous avons mis en évidence que les outils d’aide au diagnostic élaborés dans une population d’adultes jeunes avaient des performances médiocres dans la population âgée. Nous avons également pu mettre en évidence que les tableaux cliniques habituellement décrits de la maladie ne sont pas ceux observés le plus fréquemment dans une population de sujets de 65 ans ou plus. Ces observations ont abouti à l’élaboration un outil d’aide au diagnostic (score) spécifique à cette population. De nombreuses questions subsistent concernant cette infection, notamment sur les conséquences à moyen et long terme, sachant les conséquences en phase aiguë et l’existence de formes chroniques. Une étude préliminaire que nous avons conduit suggère l’absence de surmortalité à moyen terme (un an) et la majoration de la dépendance dans les suites d’une infection par le virus du Chikungunya. D’autres travaux seront nécessaires pour caractériser la forme habituelle de la maladie chez les sujets âgés ainsi que pour mieux appréhender les conséquences à moyen et long terme concernant la mortalité et la dépendance. / Chikungunya virus infection is an emergent arthropod-borne alpha-virus transmitted by mosquito bites, and causes fever with debilitating arthritic illness. Chikungunya virus infection is still considered as an emerging public health problem in both tropical and temperate regions. The presence of favourable conditions in temperate regions has enabled propagation of the vector, leading to the emergence of the first autochthonous cases of CHIKV in Europe and the USA. Older people may be particularly concerned about infection during an outbreak. CVhikungunya virus infection prevalence rates are not fully known, and vary from 18% to 48% The use of predictive scores would thus be very helpful in this situation. We have showed that predictive scores developed in young population have poor diagnostic performances in elderly population. In fact, the populations described in observational studies of chikungunya virus infection were predominantly young subjects. Clinical and epidemiological data in older subjects (aged 65 and over) are sparse. The mortality and morbidity related to infection in elderly people is poorly documented. We showed that the usual clinical expression of CHIKV infection is different in elderly subjects (absence of fever, arthralgia or both). We have developed and validated a new Chikungunya virus infection screening score specifically for use in the aged population.Some questions remain, in particular concerning mid- or long-term consequences of infection in elderly people. In a preliminary study, we have showed that the mid-term mortality rate of aged people infected by Chikungunya was lower than that of uninfected aged people.We need to continue our work on this thematic to explore more precisely the consequences of chikungunya virus infection in elderly people (mid- and long-term mortality, loss of autonomy, chronic form…).

Orientador: Ana Carolina Gomes Jardim / Resumo: Nas últimas décadas, diversos vírus que tinham sua ocorrência limitada a pequenas regiões se espalharam pelo globo, causando epidemias e preocupação entre as autoridades de saúde. Apesar dos inúmeros avanços no tratamento das infecções virais, vários destes vírus ainda não possuem tratamento especifico e eficaz. Adicionalmente, a alta taxa de resistência e o surgimento de novas mutações, torna a busca por novos antivirais desafiadora e de extrema importância. Desta forma, o presente trabalho teve como objetivo investigar a atividade antiviral de compostos de origem natural ou sintética contra os vírus da Chikungunya (CHIKV) e Enterovirus A71 (EV-A71). Contra o CHIKV, 48.750 compostos sintéticos foram inicialmente avaliados in silico por docking molecular, dos quais 12 compostos demonstraram apresentar interação com a região de ligação a ADP-ribose do dominío macro da proteína viral não estrutural 3 (nsP3), e foram selecionados para ensaios in vitro. Ensaios de viabilidade celular foram realizados para determinar a máxima concentração não tóxica de cada composto, que foi utilizada nos ensaios anti-CHIKV em células de hepatocarcimona humano Huh-7, transfectadas com os replicons subgenômicos do CHIKV. Os resultados demonstraram que os compostos C5 e C13 na concentração de 20 µM inibiram 53 e 76% da replicação do CHIKV em células Huh-7, respectivamente. Contra o EV-A71, 6 proteínas isoladas da peçonha de serpentes foram testadas em concentrações não tóxicas em células Vero infect... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: In the last decades, several viruses that had their occurrence limited to small regions spread through the globe, causing epidemics and concern among health authorities. Despite the numerous advances in the treatment of viral infections, several of these viruses have no specific and effective treatment yet. In addition, the high rate of resistance and the emergence of new mutations, makes the search for new antivirals challenging and extremely important. The present work aimed to investigate the antiviral activity of compounds from natural or synthetic origin against Chikungunya virus (CHIKV) and Enterovirus A71 (EV-A71). Against CHIKV, 48,750 synthetic compounds were initially evaluated in silico by molecular docking, of which 12 compounds demonstrated to be interacting with the ADP-ribose binding region of viral non- structural protein 3 (nsP3) macro domain and were selected for in vitro assays. Cell viability assays were performed to determine the maximum non-toxic concentration of each compound and used in anti-CHIKV assays in human hepatocarcinoma cells (Huh-7) transiently transfected with the CHIKV subgenomics replicons. The results demonstrated that the C5 and C13 compounds at 20 µM inhibited 53 and 76% of CHIKV replication in Huh-7 cells, respectively. Against EV-A71, 6 proteins isolated from snake venom were tested at non-toxic concentrations in infected Vero cells, and the virucidal, protective and anti-EV-A71 replication activity was evaluated. From the tested toxi... (Complete abstract click electronic access below) / Doutor

Arbovirus infections are widespread, and their disease burden has increased in the past decade. In Africa, arbovirus infections and fever with unknown etiology are common. Due to the lack of well-established epidemiologic surveillance systems and accurate differential diagnosis in most African countries, little is known about the prevalence of human arbovirus infections in Africa. The aim of this review is to summarize the available epidemiological data and diagnostic laboratory tools of infections with dengue, yellow fever, Zika, and chikungunya viruses, all transmitted by Aedes mosquitoes. Studies indicate that these arboviral infections are endemic in most of Africa. Surveillance of the incidence and prevalence of the infections would enable medical doctors to improve the diagnostic accuracy in patients with typical symptoms. If possible, arboviral diagnostic tests should be added to the routine healthcare systems. Healthcare providers should be informed about the prevalent arboviral diseases to identify possible cases.

Using reverse genetics, we analyzed a chikungunya virus (CHIKV) isolate of the Indian Ocean lineage lacking direct repeat (DR) elements in the 3′ untranslated region, namely DR1a and DR2a. While this deletion mutant CHIKV-∆DR exhibited growth characteristics comparable to the wild-type virus in Baby Hamster Kidney cells, replication of the mutant was reduced in Aedes albopictus C6/36 and Ae. aegypti Aag2 cells. Using oral and intrathoracic infection of mosquitoes, viral infectivity, dissemination, and transmission of CHIKV-∆DR could be shown for the well-known CHIKV vectors Ae. aegypti and Ae. albopictus. Oral infection of Ae. vexans and Culex pipiens mosquitoes with mutant or wild-type CHIKV showed very limited infectivity. Dissemination, transmission, and transmission efficiencies as determined via viral RNA in the saliva were slightly higher in Ae. vexans for the wild-type virus than for CHIKV-∆DR. However, both Ae. vexans and Cx. pipiens allowed efficient viral replication after intrathoracic injection confirming that the midgut barrier is an important determinant for the compromised infectivity after oral infection. Transmission efficiencies were neither significantly different between Ae. vexans and Cx. pipiens nor between wild-type and CHIKV-∆DR. With a combined transmission efficiency of 6%, both Ae. vexans and Cx. pipiens might serve as potential vectors in temperate regions.

Alphaviruses are a group of medically relevant arthropod-borne viruses (arboviruses) belonging to the Togaviridae family that are maintained by mosquito vectors. These zoonotic viruses are clustered into two groups: New World and Old World, depending on their geographical origin/distribution and clinical manifestations. Both of these groups cause disease symptoms of an acute febrile illness; however, each group has a distinct, hallmark disease symptom; New World alphaviruses, such as Eastern, Western, and Venezuelan equine encephalitis viruses (EEEV, WEEV, and VEEV, respectively), present with severe encephalitis while Old World alphaviruses, such as Sindbis, chikungunya, and Mayaro viruses (SINV, CHIKV, and MAYV, respectively) present with an incapacitating polyarthralgia that can persist for years following initial infection. To date, the most effective means of controlling these arboviral infections is through mosquito control programs. However, these programs have crucial limitations in their effectiveness; therefore, novel approaches are necessary to control the spread of these crippling pathogens and lessen their disease burden. Given the close phylogenetic and antigenic relationship between MAYV and CHIKV, we hypothesized that prior CHIKV immunity may affect the outcome of MAYV disease and/or limit its emergence in humans. Our work has shown that anti-CHIKV neutralizing antibodies can provide cross-protective immunity against MAYV disease. Alongside these studies, we have characterized the potency of a camelid-derived single-domain antibody (sdAb) that neutralizes a breadth of alphaviruses, including CHIKV and MAYV. With these data, we have designed and generated transgenic Aedes aegypti mosquitoes that express two anti-CHIKV sdAbs to target infection, dissemination, and transmission of MAYV and CHIKV within this deadly vector. These findings are particularly significant because they highlight the ability to co-target two emerging alphaviruses that are crippling public health and obliterating quality of life around the globe within a single defense strategy. / Doctor of Philosophy / Alphaviruses are arthropod-borne viruses (arboviruses) belonging to the Togaviridae family that infect millions of people annually via the bite of female mosquitoes. These viruses are major public health threats due to their ability to infect humans and animals and infections resulting in a range of debilitating diseases. Viruses within this genus are clustered into two groups: Old World and New World, based on geographical origin and distribution. While New World alphaviruses are known for inducing severe encephalitis (i.e., swelling in the brain), a hallmark symptom of the Old World alphaviruses is the development of incapacitating polyarthralgia (i.e., widespread joint pain) that can persist for years following initial infection. To date, the most effective means of combatting these viruses is through mosquito control programs. However, these programs have crucial limitations in their effectiveness; therefore, novel approaches are necessary to control the spread of these crippling pathogens. Given the close genetic relationship between chikungunya virus (CHIKV) and Mayaro virus (MAYV), our research has focused on harnessing cross-reactive immunity between these emerging alphaviruses. We discovered this cross-reactivity provides protective immunity to both viruses (i.e., CHIKV and MAYV) after exposure to only one (i.e., CHIKV) of the viruses. Next, we characterized the potency of a small, single-domain antibody (sdAb) to neutralize a breadth of alphaviruses, including CHIKV and MAYV. With these data, we have designed and generated transgenic Aedes aegypti mosquitoes that express this sdAb to target both CHIKV and MAYV within this deadly mosquito vector. These findings are particularly significant because they provide the foundation for a novel approach to controlling and preventing outbreaks of these emerging alphavirus pathogens that obliterate quality of life in public health settings around the globe.

The world is grappling with an escalating risk of viral outbreaks of pandemic proportion, with zoonotic RNA viruses such as chikungunya virus (CHIKV) and SARS-CoV-2 posing significant threats to global health. Several environmental and evolutionary factors have fueled the emergence and spread of infection, creating a constant arms race against emerging pathogens. Current prevention and mitigation strategies are inadequate, necessitating tools to prevent and control viral infections; innovative strategies are needed in the pipeline to address significant challenges. CHIKV is a mosquito-borne virus that has caused millions of disease cases worldwide and is a reemerging threat with increasing potential to become endemic in the US. Currently, there are no licensed treatments available to protect against CHIK disease, making the development of a vaccine crucial. Live-attenuated vaccines (LAVs) have traditionally been a promising strategy due to their high immunogenicity and cost-effectiveness. However, concerns regarding adverse side effects and the potential for viral replication leading to pathogenic reversions or transmission into mosquitoes have limited their use. To that end, we have developed a new generation of safer vaccines by modifying the standard LAV platform through innovative attenuating strategies. Our dual-attenuated platform utilizes a previously developed chimera of CHIKV and the closely related Semliki Forest virus (SFV) as a vaccine backbone which expresses antiviral mouse cytokines IFN-γ or IL-21, as an additional mechanism to control infection. In several mouse models, both cytokine-expressing candidates showed reduced footpad swelling and minimal to no systemic replication or dissemination capacity compared to the parental vaccine post-vaccination. Importantly, these candidates conferred full protection from wildtype CHIK disease. Our IFNγ-expressing vaccine showed the most significant attenuation of viral replication. To understand the underlying mechanism, we identified three IFNγ-regulated antiviral genes (Gbp1/2 and Ido1) that were highly upregulated in 3T3 mouse fibroblasts post-infection with the IFN-γ-expressing candidate but not the parental backbone. To further investigate the role of these genes in restricting viral replication and enhance the clinical relevance of our vaccine platform, we redesigned our vaccine to express human IFNγ (hIFNγ) and performed viral growth kinetics in MRC5 human lung fibroblasts. Our vaccine showed reduced viral replication compared to controls and high expression of human GBP1/2/3 was observed post-infection. Overexpression of these genes demonstrated a direct impact on viral replication against wildtype CHIKV. These findings shed light on the mechanism of action of our vaccine and highlight the potential of targeting IFNγ-regulated antiviral genes for developing effective vaccines against CHIKV. Our results provided a foundation for investigating the broad-use application of IFN-γ against other alphaviruses for vaccine or therapeutic design. We evaluated the effects of increasing levels of exogenous hIFNγ on Mayaro virus (MAYV), Ross River virus (RRV), and Venezuelan Equine Encephalitis virus (VEEV). We observed a positive dose-dependent relationship between hIFNγ and decreasing viral titers for all three viruses. Interestingly, we also observed similar patterns of GBP upregulation with MAYV and RRV, both Old World alphaviruses, but not with VEEV, a New World alphavirus. This finding may indicate an alternative IFNγ-stimulated pathway responsible for controlling different alphaviruses. Overall, these studies establish a fundamental role of IFNγ in controlling viral infection and highlight its potential use in both vaccine and therapeutic intervention. While LAVs are a gold standard for developing immunity against a virus, the urgency of responding to an active and deadly pandemic has promoted the use of faster strategies such as mRNA vaccines. Once the viral sequence was known, these vaccines were comparatively quick to produce for SARS-CoV-2 and prevented millions of disease cases at the height of their introduction. However, the emergence of variants of concerns bypassing previous immunization efforts has demonstrated the need for complementary treatments such as antivirals to control disease. To that end, we evaluated several rhodium organometallic complexes as potential antivirals against SARS-CoV-2. We show that two pentamethylcyclopentadienyl (Cp*) rhodium piano stool complexes, Cp*Rh(ICy)Cl2 and Cp*Rh(dpvm)Cl are non-toxic in Vero E6 and Calu3 cells and reduce SARS-CoV-2 plaque formation up to 99%. These complexes have previously demonstrated high antimicrobial activity against multiple antibiotic-resistance bacteria and with our results, support their potential application as pharmaceuticals, warranting further investigation into their activity. / Doctor of Philosophy / The global response to the COVID-19 pandemic, and its far-reaching impact, revealed significant shortcomings in public health preparedness for emerging viruses. Despite efforts to develop vaccines and antivirals to prevent and treat disease, current mitigation strategies have proven insufficient to eradicate the pathogen. The emergence of viral outbreaks caused by viruses such as chikungunya (CHIKV) and SARS-CoV-2 underscores the ongoing threat posed by emerging infectious diseases. Improved countermeasures are urgently needed to address gaps in vaccine and antiviral development. CHIKV is a mosquito-borne virus that has caused millions of infections across hundreds of countries with the emergent potential to become endemic in the US. Currently, there are no vaccines available to the public; therefore, it is important to generate and administer an effective vaccine before further spread of the virus. To this end, we developed innovative live-attenuated vaccines (LAVs) against CHIKV using a weakened chimeric backbone of CHIKV and its close relative, Semliki Forest virus (SFV), along with vaccine-driven expression of antiviral cytokines to control viral replication. Vaccination of highly susceptible mice with these cytokine-expressing vaccines produced significantly decreased side-effects compared to the parental virus not expressing the cytokines. Additionally, these viruses had significantly restricted viral replication capabilities while robustly protecting mice from a semi-lethal CHIKV infection. Our interferon-gamma (IFNγ) expressing vaccine had the greatest impact on viral replication, and we investigated the mechanism leading to this attenuation. To assess the clinical relevance of our vaccine platform, we redesigned the virus to express human IFNγ and identified a specific pattern of IFNγ-stimulated genes that are potentially responsible for limiting CHIKV replication. Furthermore, we demonstrated the broad therapeutic use of IFNγ against other medically relevant alphaviruses. Overall, these studies establish an improved mechanism to create safer vaccines without compromising efficacy and highlight the therapeutic potential of IFNγ against alphaviruses. Lastly, in a collaborative effort to respond to the COVID-19 pandemic, we also explored and characterized the use of a new class of antiviral drugs. With the advent of increasing drug resistance, it is essential to develop novel and resilient therapeutics. We demonstrated the first antiviral potential of rhodium organometallics, which was previously shown to be effective against multiple antibiotic-resistant bacteria. Two complexes demonstrated high virucidal activity against SARS-CoV-2 and low toxicity in mammalian cell lines. Moreover, these complexes can be further derivatized to improve efficacy, making them a promising new antiviral strategy.

Les virus sont des parasites intracellulaires obligatoires recrutant des cofacteurs cellulaires afin de détourner les différents processus biologiques leur permettant notamment de répliquer leur génome et de former d'autres particules virales. Si des cofacteurs cellulaires de la réplication du virus Semliki Forest ont été récemment identifiés, très peu d'études ont permis de révéler des partenaires de la réplication du proche Alphavirus Chikungunya (CHIKV). Nous avons découvert, au cours de cette étude, un recrutement d'Hélicases à domaine DExD/H au niveau de sites de réplication du CHIKV. Parmi elles, DHX9 ou RNA Helicase A (RHA), grâce à ses propriétés de liaison et de modulation de structures des ARNs ou de complexes de Ribonucléoprotéines, est impliquée dans diverses fonctions depuis la transcription, la traduction, la réplication de génomes et jusqu'à la production de particules infectieuses de nombreux virus. Dans le cas du virus Chikungunya, nous avons caractérisé une fonction provirale dans la traduction de protéines non-structurales et une fonction antivirale dans la réplication du génome. Cette double fonction opposée est manipulée par le CHIKV afin d'assurer une production de protéines non-structurales composant le complexe de réplication tout en maintenant sa réplication. Ces travaux révèlent un nouveau mécanisme de régulation de la traduction d'ARN génomique de CHIKV et apportent des éléments de compréhension dans la dynamique de passage du phénomène de traduction à l'étape de réplication du génome CHIKV. / Viruses are obligate intracellular parasites recruiting cellular cofactors to divert different biological processes enabling them to replicate their genome and to form other viral particles. If cellular cofactors of Semliki Forest virus replication have recently been identified, very few studies have revealed the replication partners of the very close Alphavirus Chikungunya (CHIKV). During this study, We have discovered recruitments of several DExD/H Box Helicases at the CHIKV replication sites. Among them, DHX9 or RNA Helicase A (RHA) through its RNA binding properties and in modulating RNA secondary structures or Ribonucleoproteins complexes, is involved in various functions from transcription, translation, replication of genomes and up to production of infectious particles of many viruses. In the case of Chikungunya virus, we have characterized a proviral function in the translation of non-structural proteins and an antiviral function in the genome replication. These opposite functions are manipulated by CHIKV to ensure production nonstructural proteins, components of the CHIKV replication complex while maintaining its replication. These works reveal a new translation regulation mechanism of CHIKV genomic RNA and bring some knowledge on the passage from the translation stage to the replication step of CHIKV genome.

Le virus Chikungunya (CHIKV), arbovirus en pleine ré-émergence, a envahi rapidement de nombreuses zones géographiques du monde. La propagation mondiale de ce virus constitue une menace pour la santé humaine car il n'y a pas de vaccin ou d'agents antiviraux appropriés pour contrôler l'infection virale. La transmission du virus s’effectue lors de la piqure d’un moustique infecté du genre Aedes, qui injecte sa salive contenant le virus dans la peau de l’hôte humain. Afin de contrôler la dissémination du virus, il est primordial de développer des recherches sur l’identification de molécules antivirales et de comprendre les mécanismes moléculaires impliqués dans les interactions hôte-virus et/ou vecteur-virus-hôte. En utilisant différentes stratégies moléculaires et cellulaires, nous avons étudié le potentiel antiviral de l'Imipramine, une molécule déjà commercialisée et qui a la capacité de perturber le transport du cholestérol intracellulaire. Nous avons démontré que cette molécule est capable d'inhiber la réplication du CHIKV dans les fibroblastes cutanés humains. Nous avons mis en évidence que l'Imipramine affectait à la fois les étapes de fusion et de réplication pendant le cycle de réplication du virus. En outre, la molécule a également fortement inhibé la réplication de plusieurs Flavivirus comme le virus Zika (ZIKV), le virus du Nil occidental et le virus de la Dengue. Nous avons également déterminé le profil protéomique global des fibroblastes humains infectés par le CHIKV ou le ZIKV. Cela nous a permis de mettre en évidence les modulations significatives de plusieurs protéines stimulées par l'interféron et de protéines impliquées dans à la défense anti-virale dans les cellules infectées. Plus important encore, nos résultats montrent pour la première fois le rôle de la protéine SAMHD1 dans l'infection des fibroblastes cutanés par les arbovirus. Enfin, compte tenu des fortes interactions entre l’hôte, le vecteur et le CHIKV, l'effet de la salive du moustique Ae. Aegypti sur l'infection virale a été étudié. À notre connaissance, cette étude est la première à montrer l’importance de la salive d’Ae. aegypti sur la facilitation de l’infection du CHIKV, dans des fibroblastes cutanés, à travers la régulation des gènes impliqués dans la réponse interféron de type I. / Chikungunya virus (CHIKV) is a re-emerging mosquito-borne alphavirus that has been spread worldwide. The dissemination of this virus is a threat to human health since there is no approved vaccine or appropriate antiviral agents to control viral infection. The global expansion of the virus is preceded by biting of infected Aedes mosquitos, which injects saliva containing the virus into the skin of the human host. Searching for effective antiviral compounds and understanding of the molecular mechanisms involved in host-virus or vector-virus-host interactions are crucial for controlling viral spread.Using different molecular and cellular strategies, we demonstrated that the FDA approved drug, imipramine, which has the capability to disturb intracellular cholesterol transport inhibits CHIKV replication in human skin fibroblasts. Imipramine was found to affect both the fusion and replication steps of the viral life cycle. Moreover, it also strongly inhibited the replication of several Flaviviridae family members, including Zika, West Nile and Dengue virus. We have also determined the global proteomic profile of Chikungunya and Zika virus infected human skin fibroblasts, and found that several interferon-stimulated proteins and antiviral response proteins are significantly up-regulated in the infected cells. More importantly, our results also provided for the first time a role of SAMHD1 in arbovirus infection of human skin fibroblasts. Finally, we demonstrated that Aedes aegypti saliva enhances CHIKV replication in human skin fibroblasts. To our knowledge, this is the first report showing the importance of Aedes aegypti saliva on promoting CHIKV infection via down regulation of the genes involving type I IFN secretion in the infected human cutaneous cells.

Dans différents domaines de recherche, la modélisation est devenue un outil efficace pour étudier et prédire l’évolution possible d’un système, en particulier en épidémiologie. En raison de la mondialisation et de la mutation génétique de certaines maladies ou vecteurs de transmission, plusieurs épidémies sont apparues dans des régions non encore concernées ces dernières années. Dans cette thèse, un modèle décrivant la transmission de l’épidémie de chikungunya à la population humaine est étudié. Ce modèle prend en compte la mobilité spatiale des humains, ce qui est nouveau. En effet, c’est un facteur intéressant qui a influencé la réapparition de plusieurs maladies épidémiques. Le déplacement des moustiques est omis puisqu’il est limité à quelques mètres. Le modèle complet (modèle EDOs-EDPs) est alors composé d’un système à réaction-diffusion (prenant la forme d’équations différentielles partielles (EDPs) paraboliques semi-linéaires) couplé à des équations différentielles ordinaires (EDOs). Nous démontrons pour ce modèle, d’abord l’existence et l’unicité de la solution globale, sa positivité et sa bornitude, puis nous donnons quelques simulations numériques. Dans ce modèle, certains paramètres ne sont pas directement accessibles à partir des expériences et doivent être estimés numériquement. Cependant, avant de rechercher leurs valeurs, il est essentiel de vérifier l’identifiabilité des paramètres pour déterminer si l’ensemble des paramètres inconnus peut être déterminé de manière unique à partir des données. Cette étude permettra de s’assurer que les procédures numériques peuvent être couronnées de succès. Si l’identifiabilité n’est pas assurée, certaines données supplémentaires doivent être ajoutées. En fait, une première étude d’identifiabilité a été effectuée pour le modèle EDOs en considérant que le nombre d’œufs peut être facilement compté. Toutefois, après avoir discuté avec les chercheurs épidémiologistes, il apparaît que c’est le nombre de larves qui peut être estimé semaines par semaines. Ainsi, nous ferons une étude d’identifiabilité pour le nouveau modèle EDOs-EDPs avec cette hypothèse. Grâce à l’intégration de l’une des équations du modèle, on obtient des équations plus faciles reliant les entrées, les sorties et les paramètres, ce qui simplifie vraiment l’étude d’identifiabilité. A partir de l’étude d’identifiabilité, une méthode et une procédure numérique sont proposés pour estimer les paramètres sans en avoir connaissance. / In different fields of research, modeling has become an effective tool for studying and predicting the possible evolution of a system, particularly in epidemiology. Due to the globalization and the genetic mutation of certain diseases or transmission vectors, several epidemics have appeared in regions not yet concerned in the last years. In this thesis, a model describing the transmission of the chikungunya epidemic to the human population is studied. As a novelty, this model incorporates the spatial mobility of humans. Indeed, it is an interesting factor that has influenced the re-emergence of several epidemic diseases. The displacement of mosquitoes is omitted since it is limited to a few meters. The complete model (ODEs-PDEs model) is then composed of a reaction-diffusion system (taken the form of semi-linear parabolic partial differential equations (PDEs)) coupled with ordinary differential equations (ODEs). We prove the existence, uniqueness, positivity and boundedness of a global solution of this model at first and then give some numerical simulations. In such a model, some parameters are not directly accessible from experiments and have to be estimated numerically. However, before searching for their values, it is essential to verify the identifiability of parameters in order to assess whether the set of unknown parameters can be uniquely determined from the data. This study will insure that numerical procedures can be successful. If the identifiability is not ensured, some supplementary data have to be added. In fact, a first identifiability study had been done for the ODEs model by considering that the number of eggs can be easily counted. However, after discussing with epidemiologist searchers, it appears that it is the number of larvae which can be estimated weeks by weeks. Thus, we will do an identifiability study for the novel ODEs-PDEs model with this assumption. Thanks to an integration of one of the model equations, some easier equations linking the inputs, outputs and parameters are obtained which really simplify the study of identifiability. From the identifiability study, a method and numerical procedure are proposed for estimating the parameters without any knowledge of them.

Dans le but de rechercher de nouveaux inhibiteurs de l’ARN polymérase NS5 du virus de la dengue (DENV), un criblage a été mené sur 650 plantes néo-calédoniennes. A la suite de ce criblage, deux espèces (Cryptocarya chartacea Kostermans et Trigonostemon cherrieri Veillon) ont été sélectionnées. L’extrait AcOEt des écorces de Cryptocarya chartacea (Lauraceae) a montré une forte inhibition de la NS5 polymérase (99 % à 10 µg/ml). L’étude phytochimique de l’extrait a mis en évidence une série de nouvelles flavanones 6-mono et 6,8-dialkylées, nommées chartacéones. Celles-ci sont présentes sous forme de mélanges racémiques au sein de C. chartacea. La chartacéone A a été purifiée sur colonne chirale conduisant à l’isolement de quatre diastéréoisomères optiquement purs. Une étude configurationnelle basée sur le calcul théorique de spectres de dichroïsme circulaire a permis la détermination de leur configuration absolue. Les chartacéones inhibent de façon sélective la NS5 polymérase du DENV. L’étude des extraits AcOEt des écorces et du bois de Trigonostemon cherrieri (Euphorbiaceae) a mis en évidence une série de métabolites secondaires originaux de type Diterpènes Daphnane Orthoester (DDO) chlorés : les trigocherrines (non-macrocycliques) et les trigocherriolides (macrocycliques). Ces composés ont montré une inhibition de l’activité enzymatique de la NS5 polymérase du DENV et une activité antivirale sur le virus du chikungunya in cellulo. / In order to identify new inhibitors of the dengue virus (DENV) NS5 RNA polymerase, a screening was led on 650 new-caledonian plants. Two species, Cryptocarya chartacea Kostermans and Trigonostemon cherrieri Veillon were selected. The EtOAc bark extract of Cryptocarya chartacea (Lauraceae) showed a potent inhibition of the NS5 polymerase activity (99 % at 10 µg/ml). The phytochemical study of the extract led to the isolation of a series of new 6-mono and 6,8-dialkylated flavanones, called chartaceones. Chartaceones are present as racemic mixtures in the plant. Chartaceone A was purified on chiral column leading to the isolation of 4 optically pure diastereoisomers. A configurational study based on the theoretical calculation of circular dichroism spectra allowed the determination of their absolute configuration. Chartaceone are selective inhibitors of the DENV NS5 polymerase. The study of the EtOAc extract from the bark and wood of Trigonostemon cherrieri (Euphorbiaceae) led to the isolation of a series of unusual chlorinated daphnane diterpene orthoesters (DDO) : trigocherrins (non macrocylic) and trigocherriolides (macrocyclic). These compounds inhibit the DENV NS5 polymerase activity and present an antiviral activity on the chikungunya virus in cellulo.